As an adjuvant used in antitumor and anti-radiation therapies, CSI enhances erlotinib’s antitumor effects through inhibiting of the KRAS pathway, suggesting CSI’s potential as an adjunctive therapy specifically targeting KRAS-mutated pancreatic cancer. This evidence concerns the gene KRAS and familial pancreatic carcinoma.